suvaxyn circo+mh rtu
zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.
porcilis pcv m hyo
intervet international b.v. - porcine circovirus type 2 (pcv2) orf2 subunit antigen, mycoplasma hyopneumoniae j strain inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs (for fattening) - for the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues, virus shedding caused by porcine circovirus type 2 (pcv2) infection, and severity of lung lesions caused by mycoplasma hyopneumoniae infection. to reduce the loss of daily weight gain during the finishing period in face of infections with mycoplasma hyopneumoniae and/or pcv2 (as observed in field studies)
ingelvac circoflex suspension for injection in pigs
boehringer ingelheim animal health australia pty. ltd. - porcine circovirus type 2 orf2 protein; carbomer - misc. vaccines or anti sera - porcine circovirus type 2 orf2 protein vaccine-viral active 1.0 ml/do; carbomer ungrouped other 1.0 mg - immunotherapy - pigs - see label for type - disease control
porcilis pcv m hyo
intervet australia pty limited - porcine circovirus type 2 orf2 subunit antigen; mycoplasma hyopneumoniae - inactivated antigen - vaccine or antisera - porcine circovirus type 2 orf2 subunit antigen vaccine-viral active 1414.0 au/ml; mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 2.69 rp - immunotherapy
suvaxyn circo
zoetis belgium sa - porcine circovirus vaccine (inactivated, recombinant) - immunologicals for suidae, inactivated viral vaccines - pigs (for fattening) - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.,
mhyosphere pcv id
laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.
ingelvac circoflex
boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs over the age of two weeks against porcine circovirus type 2 (pcv2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with pcv2-related disease (pcvd).in addition, vaccination has been shown to reduce pcv2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.onset of protection occurs as early as two weeks post vaccination and lasts for at least 17 weeks.
ingelvac pcv flex
boehringer ingelheim vetmedica gmbh - porcine circovirus type 2 orf2 protein - immunologicals for suidae - pigs - for active immunisation of pigs with no pcv2 maternally derived antibodies from the age of 2 weeks against porcine circovirus type 2 (pcv2),
fostera gold pcv-mh formulation: each 2 ml (dose) contains: porcine circovirus (genotype 1 and type 2, 2b chimera)........ 1>.3 rp mesomycoplasma hyopneumoniae (p-5722-3 strain).............. > 1.8 rp rp - relative potency emulsion for injection (im)
zoetis philippines, inc.; distributor: zoetis philippines, inc. - inactivated porcine circovirus (pcv) , mesomycoplasma hyopneumoniae vaccine (vet.) - emulsion for injection (im) - formulation: each 2 ml (dose) contains: porcine circovirus (genotype 1 and type 2, 2b chimera)........ 1>.3 rp mesomycoplasma hyopneumoniae (p-5722-3 strain).............. > 1.8 rp rp - relative potency
suigen pcv2 formulation: each 1 ml (dose) contains: porcine circovirus (pcv) type 2 (pcv 20, h strain).....210 tcids (before inactivation) tcid- tissue culture infective dose emulsion for injection (im)
virbac philippines inc. - inactivated porcine circovirus (pcv) vaccine (vet.) - emulsion for injection (im) - formulation: each 1 ml (dose) contains: porcine circovirus (pcv) type 2 (pcv 20, h strain).....210 tcids (before inactivation) tcid- tissue culture infective dose